Bausch Health Companies Inc (TSX:BHC)

Healthcare

Bausch Health Companies Inc is a global diversified specialty pharmaceutical company that provides health care products. It majorly caters to three therapeutic areas: eye-health, gastroenterology (“GI”), and dermatology.

It is listed on the Toronto Stock Exchange and NYSE under the ticker 'BHC.'

The company was incorporated as Biovail Corporation in February 2000 due to a merger between TXM Corporation and Biovail Corporation International. In September 2010, Biovail was renamed as Valeant Pharmaceuticals International, Inc. On July 13, 2018, the company changed its corporate name to Bausch Health Companies Inc.

The multinational firm manufactures, develops and sells a broad range of branded generic medicines, over-the-counter (OTC) products and medical devices, including aesthetic devices, intraocular lenses, contact lenses and ophthalmic surgical equipment.

Bausch Health provides diversified health care products under different segments, including:

• Eye health: Bausch + Lomb

• Gastrointestinal diseases: Salix Pharmaceuticals

• Dermatology: Ortho Dermatologics

• Dentistry: OraPharma

• Aesthetics devices: Solta Medical

 

Bausch Health's pharmaceutical portfolio also caters to several therapeutic areas such as chronic pain, migraines, depression, epilepsy, and rare diseases such as Huntington's disease.

Bausch Health has a global presence in over 90 countries, Europe, Canada, the United States, the Middle East, Africa, Latin America and the Asia Pacific.

The company's global headquarters are located in Laval, Quebec, Canada, and the US headquarters are in Bridgewater, New Jersey.

Bausch Foundation, established in 2017, is a charitable foundation that reportedly provides access to safe and effective medicines and financially supports health care education across the world.

Bausch Health claims to invest in advanced research and clinical trials to provide high-quality health care products and expand its product portfolio. As part of its research and development initiatives, the global manufacturer launched various healthcare products, including Alaway®, ENVIVE™, Clear + Brilliant® and ARAZLO®.

In 2020, the company announced to separate its eye-health business, Bausch + Lomb, into an independent public-traded company.

The pharmaceutical company claims to have contributed US$10,000 to San Gerardo Hospital and donated nebulized VIRAZOLE®, chloroquine, azithromycin to local hospitals in Spain and Italy as part of COVID-19 relief efforts.